Fat in the Liver - Is It All Happening in the Genes?

Ahmed Lutful Moben¹, Sheikh Mohammad Noor E Alam², Rokshana Begum³, Md. Abdur Rahim⁴, Musarrat Mahtab⁵, Sakirul Khan⁶, Sheikh Mohammad Fazle Akbar⁷ and Mamun Al Mahtab²*

¹Kurmitola General Hospital, Dhaka, Bangladesh
²Department of Hepatology, Bangladesh Medical University, Dhaka, Bangladesh
³Department of Hepatology, Shaheed Suhrawardy Medical College, Dhaka, Bangladesh
⁴Department of Hepatology, International Medical College, Gazipur, Bangladesh
⁵Department of Biochemistry, North South University, Dhaka, Bangladesh
⁶Department of Microbiology, Faculty of Medicine, Oita University, Oita, Japan
⁷Ehime University, Ehime, Japan, Oita University, Oita, Japan and Miyakawa Memorial Research Foundation, Tokyo, Japan

*Corresponding Author: Mamun Al Mahtab, Professor, Department of Hepatology, Bangladesh Medical University, Dhaka, Bangladesh.

Received: October 21, 2025; Published: November 18, 2025

Abstract

Fatty liver is a chronic liver disease characterized by excessive accumulation of fat, especially triglycerides, in the liver effecting both hemispheres of the globe equally. It is a non-communicable pandemic, which is on the rise and is held responsible for adding huge burden of chronic hepatitis, liver cirrhosis and even hepatocellular carcinoma. Contrary to our initial belief that fatty liver is a life-style disease, it is increasingly recognized that onset and progression of chronic hepatitis and fibrosis in fatty liver is due to an interplay genetic and environmental factors. In this review, we shed light on some of the genes that have been implicated for fatty liver.

 Keywords: Fatty Liver; Gene; Steatohepatitis; Hepatic Fibrosis

References

1. Cohen JC., et al. “Human fatty liver disease: old questions and new insights”. Science 6037 (2011): 1519-1523.
2. Friedman SL., et al. “Mechanisms of NAFLD development and therapeutic strategies”. Nature Medicine7 (2018): 908-922.
3. Wong RJ., et al. “Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States”. Gastroenterology 3 (2015): 547-555.
4. Hobbs HH. “Science, serendipity, and the single degree”. Journal of Clinical Investigation10 (2018): 4218-4223.
5. Argo CK and Caldwell SH. “Epidemiology and natural history of non-alcoholic steatohepatitis”. Clinical Liver Disease4 (2009): 511-531.
6. Farrell GC and Larter CZ. “Nonalcoholic fatty liver disease: from steatosis to cirrhosis”. Hepatology 2 (2006): S99-S112.
7. Lazo M and Clark JM. “The epidemiology of nonalcoholic fatty liver disease: a global perspective”. Seminar on Liver Disease4 (2008): 339-350.
8. Yuan L and Terrrault NA. “PNPLA3 and nonalcoholic fatty liver disease: towards personalized medicine for fatty liver”. Hepatobiliary Surgery Nutrition3 (2020): 353-356.
9. Willner IR., et al. “Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease”. American Journal of Gastroenterology 10 (2001): 2957-2961.
10. Struben VM., et al. “Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds”. American Journal of Medicine1 (2000): 9-13.
11. Schwimmer JB., et al. “Heritability of nonalcoholic fatty liver disease”. Gastroenterology5 (2009): 1585-1592.
12. Kolesnikova OV., et al. “Influence of Resistance on Cardiometabolic Risk in Non-Alcoholic Fatty Liver Disease Patients Combined with Subclinical Hypothyroidism”. Metabolism - Clinical and Experimental154587 (2021).
13. Hardwick RN., et al. “Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease”. Drug Metabolism and Disposition3 (2013): 554-561.
14. Luukkonen PK., et al. “Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids”. JCI Insight16 (2019): e127902.
15. Romeo S., et al. “Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease”. Nature Genetics12 (2008): 1461-1465.
16. Yuan X., et al. “Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes”. American Journal of Human Genetics4 (2008): 520-528.
17. Anstee QM and Day CP. “The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2”. Seminar on Liver Disease3 (2015): 270-290.
18. Dai G., et al. “Association between PNPLA3 rs738409 polymorphism and nonalcoholic fatty liver disease (NAFLD) susceptibility and severity: A meta-analysis”. Medicine (Baltimore)7 (2019): e14324.
19. Grimaudo S., et al. “Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease”. Clinical Gastroenterology and Hepatology4 (2020): 935-944.e3.
20. Dongiovanni., et al. “Statin use and non-alcoholic steatohepatitis in at risk individuals”. Journal of Hepatology 63.3 (2015): 705-712.
21. Kozlitina J., et al. “Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease”. Nature Genetics4 (2014): 352-356.
22. Holmen OL., et al. “Systematic evaluation of coding variation identifies a candidate causal variant in TM6SF2 influencing total cholesterol and myocardial infarction risk”. Nature Genetics4 (2004): 345-351.
23. Mahdessian H., et al. “TM6SF2 is a regulator of liver fat metabolism influencing triglyceride secretion and hepatic lipid droplet content”. Proceedings of the National Academy of Sciences of the United States of America 24 (2014): 8913-8918.
24. Liu DJ., et al. “Exome-wide association study of plasma lipids in >300,000 individuals”. Nature Genetics 12 (2017): 1758-1766.
25. Anstee QM., et al. “Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort”. Journal of Hepatology3 (2020): 505-515.
26. Parisinos CA., et al. “Genome-wide and Mendelian randomisation studies of liver MRI yield insights into the pathogenesis of steatohepatitis”. Journal of Hepatology 2 (2020): 241-251.
27. Chen VL., et al. “Genetic variants that associate with cirrhosis have pleiotropic effects on human traits”. Liver International2 (2024): 405-415.
28. Zhou Y., et al. “Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2”. Journal of Hepatology 3 (2015): 657-663.
29. Liu YL., et al. “TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease”. Nature Communication 5 (2014): 4309.
30. Mancina RM., et al. “Transmembrane-6 superfamily member 2 (TM6SF2) E167K variant increases susceptibility to hepatic steatosis in obese children”. Digestive and Liver Disease1 (2016): 100-101.
31. Grandone A., et al. “TM6SF2 Glu167Lys polymorphism is associated with low levels of LDL-cholesterol and increased liver injury in obese children”. Pediatric Obesity2 (2016): 115-119.
32. Chen F., et al. “Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation”. Hepatology 4 (2020): 1213-1227.
33. Bolt HM and Thier R. “Relevance of the deletion polymorphisms of the glutathione S-transferases GSTT1 and GSTM1 in pharmacology and toxicology”. Current Drug Metabolism6 (2006): 613-628.
34. Khan AJ., et al. “Polymorphism in glutathione-S-transferases: a risk factor in alcoholic liver cirrhosis”. Drug and Alcohol Dependence3 (2009): 183-190.
35. Kassogue Y., et al. “Association of glutathione S-transferase (GSTM1 and GSTT1) genes with chronic myeloid leukemia”. Springerplus 4 (2015): 210.
36. Zhu Y., et al. “Association of glutathione S-transferases (GSTT1, GSTM1 and GSTP1) genes polymorphisms with nonalcoholic fatty liver disease susceptibility: A PRISMA-compliant systematic review and meta-analysis”. Medicine (Baltimore)38 (2022): e30803.
37. Arafin SM. “Association of Glutathione S Transferase M1 and T1 genotype (genetic polymorphism) with non-alcoholic fatty liver disease”. Thesis submitted to Bangladesh Medical University for partial fulfillment of Doctor of Medicine in Hepatology (2023).
38. Chavan SU., et al. “Association of GCKR and MBOAT7 genetic polymorphisms with non-alcoholic fatty liver disease”. Clinical and Experimental Hepatology1 (2024): 39-46.
39. Zain SM., et al. “Common variant in the glucokinase regulatory gene rs780094 and risk of nonalcoholic fatty liver disease: a meta-analysis”. Journal of Gastroenterology and Hepatology 1 (2015): 21-27.
40. Yang Z., et al. “Genetic variation in the GCKR gene is associated with non-alcoholic fatty liver disease in Chinese people”. Molecular Biology Reports2 (2012): 1145-1150.
41. Huang YS., et al. “Genetic variations of three important antioxidative enzymes SOD2, CAT, and GPX1 in nonalcoholic steatohepatitis”. Journal of the Chinese Medical Association1 (2021): 14-18.
42. Mazmadar KAH. “Association of genetic polymorphism of gene encoding catalase with non-alcoholic fatty liver disease”. Thesis submitted to Bangladesh Medical University for partial fulfillment of Doctor of Medicine in Hepatology (2024).
43. Zarini S., et al. “Lysophospholipid acyltransferases and eicosanoid biosynthesis in zebrafish myeloid cells”. Prostaglandins & Other Lipid Mediators (2014): 113-115:52-61.
44. Gonzalez-Pinto A., et al. “Antioxidant defense system and family environment in adolescents with family history of psychosis”. BMC Psychiatry 12 (2012): 200.
45. Masud FMMA. “Association of genetic polymorphism of gene encoding super oxide dismutase 2 enzyme with non-alcoholic fatty liver disease”. Thesis submitted to Bangladesh Medical University for partial fulfillment of Doctor of Medicine in Hepatology (2023).

Citation

Citation: Mamun Al Mahtab., et al. “Fat in the Liver - Is It All Happening in the Genes?”.Acta Scientific Medical Sciences 9.12 (2025): 51-56.

Copyright

Copyright: © 2025 Mamun Al Mahtab., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.